Aytu Biopharma Inc's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Aytu Biopharma Inc's ROA in the fourth quarter of 2026?
Aytu Biopharma Inc recorded a cumulative net loss of $-14 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -12.24%.

However, within the Healthcare sector 312 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3610, from total ROA ranking in the third quarter of 2026 at 4048.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	-15.44 %	-10.07 %	5.15 %	7.91 %	4.1 %
Y / Y Net Income Change	-	-	-	33.31 %	-
Net Income (TTM) in million	-14	-34	-24	-13	-14
Return On Assets (TTM)	-12.24 %	-28.08 %	-19.65 %	-10.64 %	-11.25 %
AYTU's Total Ranking	# 3610	# 4048	# 3304	# 3344	# 2004
Total Assets (TTM) in million	105	112	124	125	124
Seq. Total Assets Change	-5.98 %	-10.06 %	-0.65 %	0.65 %	-0.02 %
Seq. Net Income Change	-	-	-	-	-

AYTU's 5 Years Annual ROA >> Back to AYTU Management Effectiveness >> Compare AYTU ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 112
Sector	# 313
Overall	# 3243

Return On Assets Statistics
High	Average	Low
78101.31 %	5732.81 %	-19270.57 %
(Nov 30 2013)		(May 31 2014)

Financial Statements
Aytu Biopharma Inc's Assets	$ 105 million	AYTU's Balance sheet
Aytu Biopharma Inc's Income	$ 0 million	Quarterly AYTU's Income Statement
AYTU's Income by Division		See AYTU's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	-15.44 %	5.15 %	-13.46 %	-0.84 %	-48.2 %
Total Assets in million	105	124	118	136	138
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-14	-14	-16	-17	-110
Annual Return On Assets	-13.57 %	-10.92 %	-13.42 %	-12.49 %	-80.05 %

AYTU's 5 Years Annual ROA >> Back to AYTU Management Effectiveness >> Compare AYTU ROA to its Competitors

More Return On Assets Ratios
AYTU's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AYTU's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AYTU's Competitors
Subscribers only: Roa for Aytu Biopharma Inc's Suppliers
Subscribers only: Return On Assets for AYTU's Customers

You may also want to know
AYTU's Roi	AYTU's Inventory Turnover Ratio	AYTU's Growth Rates	AYTU's Dividend Comparisons
	AYTU's Profitability Ratios	AYTU's Asset Turnover Ratio	AYTU's Dividend Growth
AYTU's Roe	AYTU's Valuation Ratios	AYTU's Financial Strength Ratios	AYTU's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T08:02:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.